These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 19923550)

  • 1. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
    Salloway S; Sperling R; Gilman S; Fox NC; Blennow K; Raskind M; Sabbagh M; Honig LS; Doody R; van Dyck CH; Mulnard R; Barakos J; Gregg KM; Liu E; Lieberburg I; Schenk D; Black R; Grundman M;
    Neurology; 2009 Dec; 73(24):2061-70. PubMed ID: 19923550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
    Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
    N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
    Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
    Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
    Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
    Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
    Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
    J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study.
    Salloway S; Marshall GA; Lu M; Brashear HR
    Curr Alzheimer Res; 2018; 15(13):1231-1243. PubMed ID: 30129411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
    Novak G; Fox N; Clegg S; Nielsen C; Einstein S; Lu Y; Tudor IC; Gregg K; Di J; Collins P; Wyman BT; Yuen E; Grundman M; Brashear HR; Liu E
    J Alzheimers Dis; 2016; 49(4):1123-34. PubMed ID: 26639957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
    Ivanoiu A; Pariente J; Booth K; Lobello K; Luscan G; Hua L; Lucas P; Styren S; Yang L; Li D; Black RS; Brashear HR; McRae T
    Alzheimers Res Ther; 2016 Jun; 8(1):24. PubMed ID: 27334799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
    Liu E; Schmidt ME; Margolin R; Sperling R; Koeppe R; Mason NS; Klunk WE; Mathis CA; Salloway S; Fox NC; Hill DL; Les AS; Collins P; Gregg KM; Di J; Lu Y; Tudor IC; Wyman BT; Booth K; Broome S; Yuen E; Grundman M; Brashear HR;
    Neurology; 2015 Aug; 85(8):692-700. PubMed ID: 26208959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
    Russu A; Samtani MN; Xu S; Adedokun OJ; Lu M; Ito K; Corrigan B; Raje S; Liu E; Brashear HR; Styren S; Hu C
    J Alzheimers Dis; 2016 May; 53(2):535-46. PubMed ID: 27163805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.
    Salloway SP; Sperling R; Fox NC; Sabbagh MN; Honig LS; Porsteinsson AP; Rofael H; Ketter N; Wang D; Liu E; Carr S; Black RS; Brashear HR
    J Alzheimers Dis; 2018; 64(3):689-707. PubMed ID: 29914022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics.
    Kaufer D; Gandy S
    Neurology; 2009 Dec; 73(24):2052-3. PubMed ID: 19923549
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
    Laskowitz DT; Kolls BJ
    Neurology; 2010 Jun; 74(24):2026; author reply 2026-7. PubMed ID: 20548049
    [No Abstract]   [Full Text] [Related]  

  • 15. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single ascending dose study of bapineuzumab in patients with Alzheimer disease.
    Black RS; Sperling RA; Safirstein B; Motter RN; Pallay A; Nichols A; Grundman M
    Alzheimer Dis Assoc Disord; 2010; 24(2):198-203. PubMed ID: 20505438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
    Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
    Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bapineuzumab.
    Kerchner GA; Boxer AL
    Expert Opin Biol Ther; 2010 Jul; 10(7):1121-30. PubMed ID: 20497044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single-Ascending-Dose Study in Patients With Mild to Moderate Alzheimer Disease.
    Lu M; Brashear HR
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):326-335. PubMed ID: 29920980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.